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Abstract: Interventional techniques to manage cancer-related pain may be efficient treatment
modalities in patients unresponsive or unable to tolerate systemic opioids. However, indication
and selection of the right technique demand knowledge, which is still incipient among clinicians.
The present article summarizes the current evidence regarding the five most essential groups of
interventional techniques to treat cancer-related pain: Neuraxial analgesia, minimally invasive
procedures for vertebral pain, sympathetic blocks for abdominal cancer pain, peripheral nerve blocks,
and percutaneous cordotomy. Furthermore, indication, mechanism, drug agents, contraindications,
and complications of the main techniques of each group are discussed.
Keywords: cancer-related pain; neuraxial analgesia; vertebroplasty; sympathetic blocks; peripheral
nerve blocks; cordotomy
1. Introduction
Nociception is the process by which information about actual or potential tissue damage is
conveyed through the spinothalamic tract to the brain, where the information is processed and
interpreted, and the descending pain modulatory system is activated [1]. The interruption of
nociceptive pathways at peripheral and central levels can be an alternative treatment approach for
patients with cancer-related pain. It can be done by interventional nondestructive or neuroablatory
techniques and is particularly indicated for the management of cancer-related pain with an
unsatisfactory response to strong systemic opioids and adjuvant analgesics and/or in patients with
intolerable side effects of systemic analgesics [2]. Such pain is often referred to as refractory pain.
Most patients with cancer-related pain obtain satisfactory pain relief from medications that are
referenced in the WHO analgesic ladder [3]. However, it has been estimated that approximately
2–5% of patients with advanced cancer have inadequate control of pain with systemic analgesics [4].
These patients may alternatively benefit from interventional techniques such as neuraxial analgesia,
minimally invasive procedures for vertebral pain, sympathetic blocks for abdominal cancer pain,
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peripheral nerve blocks, and percutaneous cordotomy. The successful use of these techniques depends
on the selection of the right therapy for the right patient.
A careful assessment of the patient is important to achieve satisfactory outcomes. This assessment
includes patient characteristics, previous treatments, pain characteristics and mechanisms, patients’
preference, and skills and logistics to perform the selected invasive technique. Moreover, interventional
techniques imply risks for complications. Therefore, potential benefits and harms should be considered
for each patient [2].
The present article aims at summarizing current evidence and improving specialist clinicians’
knowledge regarding the five most essential classes of interventional techniques to treat cancer-related
pain: Neuraxial analgesia, minimally invasive procedures for vertebral pain, sympathetic blocks for
abdominal cancer pain, peripheral nerve blocks, and percutaneous cordotomy. For each technique,
we will briefly review indications, mechanisms, drug agents, current evidence, contraindications,
and complications.
2. Interventional Techniques
2.1. Neuraxial Analgesia for Cancer Pain
When systemic analgesics are exhausted, the selection of patients for neuraxial therapy (epidural
and intrathecal routes) is often based on location and mechanism of pain—especially when considering
the benefits of adding local anesthetics [5,6] or other adjuvants as clonidine/ketamine to opioids [7,8].
Patients with cancer-related pain and longer survival expectancy (>3 months) may benefit from
neuraxial therapies using implantable systems as a permanent intrathecal catheter and subcutaneous
pump, while patients with shorter life expectancy may be treated with epidural therapy with implanted
system as a catheter or port-a-catch connected to an external PCA pump [9]. The selection of device
type usually depends on survival expectancy, patients’ needs, and costs. The mechanism of neuraxial
analgesia is based on opioid binding to its receptor in the spinal cord, which reduces or blocks the
nociceptive signal conduction. Opioids may also interfere with descending pathways and modulate
the pain pathway in the midbrain. However, other anesthetic agents as bupivacaine, which has a long
duration of action and low toxicity and costs, may be used as the main spinal therapy or in addition to
opioids. Some examples of other agents are clonidine, ketamine, and neostigmine, which may improve
analgesia and reduce opioid doses [9].
A systematic review [10] analyzed the evidence regarding analgesic efficacy and side effects
of neuraxial drug administration in adult patients with cancer-related pain and found nine RCTs,
which were divided in four groups: (A) Sufentanil or morphine combined with adjuvant analgesic
(bupivacaine, clonidine, ketamine, neostigmine, or midazolam) compared with an opioid alone
(n = 4); (B) morphine or aqueous phenol in bolus compared with continuous administration (n = 2);
(C) ziconotide compared with placebo (n = 1); and (D) morphine or hydromorphone with or without
adjuvant analgesics compared with comprehensive medical management (n = 2). The studies had
different designs and methodologies, which excluded a meta-analysis. Limitations of the studies
analyzed included lack of power sample calculation, flaws in randomization, problematic control
groups, large dropouts, small study samples, patient crossing over between the treatment arms, meagre
pain mechanism descriptors, and in some studies, exaggerated focus on the company-sponsored
implantable systems—all of which reduced external, as well as internal, validity. Due to these issues,
the quality of evidence was judged as very low. However, all studies demonstrated better pain control
for all interventions analyzed. Side effects were described, and there seemed to be few significant
differences in favor of the tested interventions. We conducted a search update for the neuraxial
administration of analgesics (Nov 2018) following the same methodology as the systematic review
mentioned [10] and found two additional articles. The first is a double-blinded cross-over study
(n = 24), which was performed to investigate the effect of intrathecal dexmedetomidine as an add-on
therapy to intrathecal analgesia in patients with refractory cancer-related pain. Pain intensity and
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morphine consumption were lower with the addition of dexmedetomidine [11]. The second study
is a double-blind RCT (n = 36), which compared the efficacy and safety of an intrathecal continuous
infusion of morphine and ropivacaine versus intrathecal morphine alone for cancer-related pain.
Pain intensity and quality of life improved with the addition of ropivacaine [12]. However, major
methodological flaws were attached to both studies including lack of statistical power. Thus, the
addition of two recent RCTs did not change the conclusion of the previous published review [10].
Contraindications to neuraxial therapy may exist in fragile patients, and complications of varying
severity are described in the literature [4]. They include harm to spinal cord or fibers during punction
and catheter placement, headache after dural puncture, epidural hematoma, infections, meningitis,
and catheter migration, among others [13]. Therefore, a limited number of patients with cancer-related
pain are candidates for neuraxial therapy, which also reflects the difficulties in performing high
quality RCTs.
2.2. Minimally Invasive Procedures for Vertebral Pain: Vertebroplasty, Kyphoplasty, Radiofrequency Ablation,
and Cryoablation
Percutaneous vertebroplasty (PV), kyphoplasty (KP), radiofrequency ablation (RFA), and
cryoablation (CA) are minimally invasive procedures indicated for the relief of vertebral bone pain in
patients with metastatic lesions and/or compression fracture without neurologic sequelae. Despite the
reported effectiveness and low risk associated with these interventions, availability of trained staff,
lack of precise indications, and the high costs render the access to minimally invasive procedures
sparse [14]. Thus, the use of these procedures should be reserved for a selected cohort of patients with
severe and disabling cancer-related back pain refractory to systemic analgesic treatment.
PV usually involves percutaneous injection of a cement, polymethylmethacrylate into the vertebral
bodies, which can provide a mechanical stabilization of the lesion/compression fracture, increase bone
strength and alleviate pain. KP is a variation of PV, which is performed by inflating a balloon in the
vertebral body to make an empty space where the cement can be placed to correct vertebral height and
kyphotic irregularities. In RFA, bone tumor or metastases are ablated using the heat generated from
medium frequency alternating current. CA is an alternative to RFA in patients with metastatic bone
disease and it is performed using cryoprobes, through which cooled, thermally conductive fluids are
circulated. The area of tissue destruction created by this technique can be delimited more effectively
by computed tomography than RFA. This is a potential advantage when treating tumors adjacent to
critical anatomical structures. These techniques have gained worldwide application for back pain due
to osteoporotic and malignant vertebral collapses refractory to conservative treatment [15]. However,
the role of these techniques remains controversial, particularly in patients with advanced cancer.
Several trials suggested a possible therapeutic role of these procedures, but existing data are
often limited to series with a low number of patients, retrospective designs, or mixed populations.
The low number of patients and the poor quality of data have not yet provided evidence for
efficacy in cancer patients with vertebral tumors or metastases. Many factors confounded the
interpretation of data and included a low accrual rate, patients with different types of fractures,
unclear evaluation of fractures, other causes of pain, problematic sham designs, and lack of proper
clinical examinations to determine the causes of pain [16]. A systematic review performed in 2015
analyzed the evidence to support the performance of percutaneous procedures to treat vertebral pain
due to cancer. Articles were selected considering interventional techniques compared with analgesic
drugs or sham procedures, but noncomparative observational investigations with a minimum set
of 50 patients were also analyzed due to the sparse number of controlled studies. The authors
found five studies that met their inclusion criteria: Two regarding KP and three PV. Out of these,
only KP had a recommendation in favor of performing this intervention in patients with vertebral
tumors or metastases. However, the studies presented several weaknesses and low-quality of study
designs, which reduced significantly the strength of recommendation [17]. In an update of that review
(Nov 2018) following the same methodology [17], we identified another systematic review performed
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in 2014 with different characteristics and inclusion criteria, which also assessed treatment safety and
effectiveness of vertebroplasty and kyphoplasty for treatment of cancer-related vertebral fractures
and found only six RCTs among 150 selected studies. They compared vertebral augmentation with
traditional management and treatments for tumor control. Pain intensity, pain-related disability, and
health-related quality of life improved following kyphoplasty compared to usual care [18]. Recent
literature after 2015 still lacks substantial data [18]. The heterogeneity of study designs, outcomes, and
populations still suggests that current literature provided inconsistent data and further studies should
delineate confounding variables. In a recent document of the European Association for Palliative
Care [17], these weaknesses and the low quality of study designs were confirmed. Recommendations
for performing RFA are weak. Further RCTs of PV and KP in patients with cancer-related pain are
required to improve the strength of evidence available to recommend these procedures on large scale.
Contraindications for these invasive procedures are coagulopathy, neurological symptoms by
vertebral compression or tumor encroachment on or within the spinal cord, complete collapse of the
vertebra, presence of systemic or local infections, and certain types of lesions, such as osteoblastic
metastasis [18,19]. Complications are of concern [20,21], as cement leakage occurred in 20–70% of
patients [22–25], and cement embolism was found in 26% of patients [26]. Moreover, symptomatic
vertebral fracture may be a common adverse event after KP, but there is a higher risk of vertebral
fracture after VP than KP [27]. KP seems to be at a lower risk of cement extravasation [15]. Thus,
these procedures carry risks of substantial harm [26]. Finally, the relationship of PV, radiotherapy, and
surgery remains unresolved [15]. For the other techniques, no such data are available.
2.3. Sympathetic Blocks for Abdominal Cancer-Related Pain: Celiac Plexus Block and Superior Hypogastric
Plexus Block
The neurolytic blockade of sympathetic pathways at different levels are indicated to patients
with abdominal pain with a visceral mechanism, although abdominal pain often has concomitance
of different pathophysiological mechanisms [28]. The celiac plexus originates from the sympathetic
fibers of the splanchnic nerves raising from T5 to T12. It is the main target point where fibers to the
upper abdominal area can be blocked by one injection. Splanchnic blocks may be an alternative to
celiac block and may produce responses in those failing to respond to celiac blocks when the target
area is invaded by the tumor [29].
Celiac plexus block (CPB) was claimed for the treatment of cancer-related pain originating from
upper abdominal viscera, while the superior hypogastric plexus block (SHPB) is targeted for lower
abdominal pain. These blocks interfere with neural conduction to abolish or reduce pain. Afferent and
efferent conduction may be disrupted by injection of local anesthetics [30]. Different techniques were
developed in an attempt to achieve the best analgesia with less complications [31].
A systematic review performed in 2014 investigated the evidence to support the treatment of
adult patients with abdominal cancer-related pain with sympathetic blocks. The analysis included
papers on sympathetic blocks compared with analgesic drugs/placebo and was conducted in adult
patients with cancer-related pain. Twenty-seven studies were analyzed; 15 were RCTs, but only four
were double-blind [32]. It was concluded that there was a strong evidence that CPB, performed by
different techniques, provides good analgesic effects and/or reduces opioid consumption and some
opioid-induced adverse effects in comparison with conventional analgesic treatment [33–44]. However,
two studies performed with different techniques [38,40] found that quality of life and survival did not
seem to be affected. An update of the aforementioned systematic review (Nov 2018) following the
same methodology [32] did not find new evidence.
The most appropriate timing for performing CPB is still controversial. It was suggested that
CPB should be performed early, even in the presence of mild pain or in patients receiving low doses
of opioids [34,36–38]. However, this statement remains unproven [41]. Some authors reported that
controlling pain with analgesics and then performing the CPB was more effective than an early block
followed by pharmacotherapy [45]. In patients with abdominal-pelvic pain, who were potential
Cancers 2019, 11, 443 5 of 12
candidates to CPB or SHPB, the analgesic treatment with low doses of opioids was effective in all
patients [45]. It is likely that the efficacy of CPB depends on individual anatomical distribution, which
is likely to be distorted with the local progression of the tumor. When tumor spread involves other
somatic areas such as peritoneum or diaphragm, it is likely that the block will be less successful,
as CPB can block the sympathetic pathways for visceral pain only. Pain may worsen due to the
involvement of areas outside the territory dependent on sympathetic pathways. Indeed, no early
procedure may prevent the subsequent neural and somatic structure involvement, which seems to
be unpredictable [46]. As pain and disease progression are unforeseeable, an early block could be
disproportionate in many circumstances. On the other hand, a late block, when somatic structures are
involved, or celiac area is distorted, is likely to be unsuccessful. Thus, the decision to perform a CPB
should be based on detailed information regarding patient condition, aim of the treatment (reduction
of opioid consumption or opioid adverse effects), and patient participation in decision making.
Data regarding SHPB is sparse, as only one controlled clinical study has been produced [47].
The origin of pelvic cancer-related pain, for which the technique is claimed, is even more complex,
because different pain mechanisms may coexist due to the various overlapping structures including
muscles and nerves [45]. It is likely that this block of sympathetic pathways is unable to abolish the
nociception. According to data from literature, there is a weak recommendation in favor of using
this intervention.
General contraindications for neurolytic blocks of sympathetic pathways include tumor invasion
into the insertion site, coagulopathy, systemic or localized infection, complicated anatomy, and
bowel obstruction [2,48]. Reported complications are back pain, orthostatic hypotension, diarrhea,
retroperitoneal hematoma, bladder or ureteral injury, and inadvertent somatic nerve damage [2,48].
Different from neurolytic somatic blocks, CPB is claimed to be safe because neurological complications
are unlikely and mostly transient when performed with CT guidance.
2.4. Peripheral Nerve Blocks: Paravertebral Blocks, Blocks in the Head Region, Plexus Blocks, and
Intercostal Blocks
A logical approach for pain otherwise difficult to treat is to block peripheral nerves with local
anesthetics and thereby block the signaling of nociceptive input to the central nervous system.
The selection of which nerve block to apply is dependent on the source of pain. Therefore, the
physicians involved in administering peripheral nerve blocks must have good knowledge of the
innervation supplied from each nerve and the anatomical localization and access to the nerve.
Peripheral blocks currently reported that are applied to cancer-related pain include paravertebral
blocks, brachial plexus blocks, blocks of nerves in the head region, and intercostal nerves.
The drugs used for nerve blocks are local anesthetics, which have to be applied continuously or
intermittently because of a limited duration of action. Local anesthetic in use are lidocaine, bupivacaine,
and ropivacaine, among others. The analgesic effect is similar, while toxicity may differ in relation
to cardiac events and other local anesthetic toxic events. However, if the local anesthetic is given
within the recommended dosages, the risk for toxicity is minimal. The duration of each local anesthetic
action differs. Lidocaine is typically considered a local anesthetic of intermediate action (1.5–3 h),
while bupivacaine and ropivacaine are long-action local anesthetics (4–18 h) [49]. The duration may be
altered by additives, such as epinephrine or clonidine, and varies between different localization of the
nerve block [50]. Therefore, for long-term therapy with local anesthetics, bupivacaine or ropivacaine
is best suited, of which bupivacaine by tradition is the most frequently reported agent in use. Some
reports on the use of peripheral nerve block applied neurolytic agents such as glycerol, phenol, or
alcohol. These agents irreversibly destroy the nerve and only need a single injection for a long-term
block of the signaling of the nerve impulse.
The evidence for use of peripheral blocks is limited. A systematic review published in 2015
identified 16 papers, which reported a total of 79 cases [51]. The nerve blocks were paravertebral
blocks (10 cases), block in the head region (two cases), plexus blocks (13 cases), intercostal block
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(43 cases), and other (11 cases). Most cases experienced pain relief, many for several weeks. Except for
catheter displacement and one report of toxic effects associated with injections of butamben, an ester
local anesthetic not used in any other reports, and there were no adverse effects. This systematic
review identified no controlled trials. An update (Nov 2018) using the same methods as in the
systematic review mentioned [50] identified additionally two cases receiving interscalene continuous
plexus blocks [52], one case with plexus phenol neurolysis [53], two cases with alcohol paravertebral
neurolysis [54], and one case with a femoral nerve block [55].
In summary, the evidence for use of peripheral blocks for cancer-related pain is still anecdotal. Still,
the published cases illustrate the potential benefit from use of peripheral blocks. New techniques such
as ultrasound identification of nerves, now routinely applied for use of local anesthesia during surgical
procedures, will ease the placement of catheters for administration of local anesthetics. Moreover,
techniques to ensure that catheters do not dislodge can be improved. Thus, physicians involved
in treatment of cancer-related pain could benefit from collaboration with anesthesiologist involved
in orthopedic surgery [56]. At the time technical issues associated with continuous administration
of local anesthetics improve, new studies should compare the use of peripheral blocks to current
standard treatment of cancer-related pain. Such studies can compare patients’ preferences in relation
to inconveniences related to the use of local anesthetics (potential motor or sensory deficits and to
carry an infusion pump) against opioid adverse effects.
Local anesthetics have adverse effects related to the potential drug toxicity, to the effects from the
nerve block in itself or as a complication to the procedure. Toxicity is not a clinical issue given that the
local anesthetic is administered at recommended doses and not inadvertently injected intravascularly.
However, because of a low, but still present risk of acute toxicity (cardiac toxicity and seizures) due
to an intravascular injection, physicians administering nerve blocks should have the knowledge and
equipment available to handle such incidents. Complications related to the effect from local anesthetic
is not a major clinical issue. If, for instance, a plexus nerve block is given in a dose that paralyses
the arm, the local anesthetic dose can simply be reduced, or the infusion discontinued, and motor
function will resolve. Also, complications related to the procedure of insertion is not reported for
patients with cancer-related pain. There may be a risk for nerve injury resulting in neuropathic pain
but given that the procedure is performed by skilled personnel using adequate techniques, this risk is
small. Moreover, peripheral block is not associated with risk such as meningitis, epidural abscesses
or hematomas feared by central blocks. Neurolytic peripheral blocks, on the other hand, will result
in permanent disability if wrongly performed, and may—if correctly performed—after some time,
result in neuropathic pain caused by reinnervation. Therefore, neurolytic blocks should not be the
first-choice treatment. It should be used rarely and only in patients with expected short survival time
(<3 months).
2.5. Percutaneous Cordotomy
Percutaneous cordotomy by radiofrequency has become a viable choice due to advances on
fluoroscopic equipment and the possibility of performing the procedure under sedation instead of
general anesthesia (usual procedure in open cordotomy), which represents an advantage to fragile
patients with advanced cancer. However, this intervention causes an irreversible disruption of the
nervous conduction and, therefore, risks and consequences should be examined carefully. The selection
of patients with cancer for this procedure is based on presence of malignant unilateral pain refractory
to systemic treatment and other nondestructive interventions, life expectancy of few years or less
considering the possibility of pain recurrence (lesioned nerves may regrow, and neuropathic pain
may return), and anatomic location of the intervention that permits a safe procedure [2,57]. It is
recommended to treat unilateral pain caused by malignant pleural mesothelioma, breast cancer,
brachial plexus pain related to pancoast tumor pressure/infiltration, or unilateral leg pain. This
treatment can also be used in bilateral cancer-related pain, but bilateral interventions increase the risk
of complications and mortality [58].
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Percutaneous cordotomy is a thermal lesion caused by radiofrequency electric current in
spinothalamic tract contralateral to the side of the pain, interrupting conduction fibers and selectively
eliminating pain and temperature sensation from the affected half of the body. Its mechanism is
unclear, but alteration on descending impulse or dorsal horn modulation, damage of C fibers and
immunomodulatory effect may all play a role on pain transmission [2]. In conventional radiofrequency,
the needle tip is heated between 80 ◦C and 90 ◦C, while in pulsed radiofrequency, the temperature is
kept below 43 ◦C to avoid tissue harm [2]. Radiofrequency lesions may be done at several sites, but
main entry point is located over the C1/2 intervertebral foramen on the opposite side of the source of
pain and may only be suitable to treat pain below the level of the C4 dermatome [58].
Retrospective and uncontrolled studies suggested that percutaneous cordotomy is effective in
reducing pain, and decreasing or discontinuing opioid use [59–61]. However, we performed a search
using the words cordotomy, pain, and cancer on PubMed (Nov 2018). The search revealed a lack
of controlled studies and very few recent prospective studies about the effects of this treatment
in cancer-related pain as demonstrated by the limited number of case studies/series [62–64] and
narrative [65] and systematic reviews [66] published in the last six years. The case-series showed
positive effects of percutaneous cordotomy alone or in combination with intrathecal neuromodulation
in 45 retrospective and five prospective cases involving cancer-related pain [63,64]; the case study of
two patients reported positive effects of percutaneous cordotomy in only one [62], while the systematic
review of case-series involving 160 patients pointed out that the procedure seemed to be effective and
safe. However, evidence was very limited in terms of quantity and quality [65,66].
The side effects of this procedure include numbness and dysesthesias below the level of the lesion.
Contraindications are abnormal coagulation, infection, severe respiratory dysfunction, and advanced
disease that hinders positioning the patient correctly during the procedure [58]. Bilateral cordotomy
procedures are generally not recommended at the high cervical region due to risk of respiratory
depression. Possible complications include hemiparesis, respiratory irregularities, bladder and bowel
dysfunction (usually temporary), and ataxia [57].
3. Considerations
The present review is not exhaustive regarding interventional techniques to the management
of refractory cancer-related pain. However, other invasive techniques, e.g., midline myelotomy and
stereotactic cingulotomy, are otherwise promising based on very few up-to-date small size series [67,68].
Despite the limited scientific evidence, all interventional techniques described in the present review
seem to provide pain relief to patients with cancer-related pain of difficult management or of intractable
nature (Table 1). However, careful attention of technique and equipment selection, dexterity to perform
the procedure, sufficient logistics and staff skills, appropriate indication based on accurate clinical
diagnosis and well-defined/localized pain, assessment of benefits/risks and contemplation of patient’s
wish/agreement are indispensable. In addition, indication for cancer-related pain should also consider
patient’s health status, estimate of survival time, and needs in order to avoid complications and qualify
proper intervention selection.
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Table 1. Summary of the systematic reviews accessed.
Reviews Neuraxial analgesia [10] Minimally invasive procedures
for vertebral pain [17]
Sympathetic blocks for abdominal cancer
pain [32]
Peripheral nerve blocks [51] Percutaneous
cordotomy [66]
Number of studies
analysed
9 (RCTs) 5 (1 RCT, 4 case-series) 15 (RCTs) 16 (case-histories/series) 9 (case-series)
Technique, number of
studies (sample) size
 Opioid and adjuvant analgesic
compared with neuraxial opioid
alone, 4 (n = 22–85)
 Single drug in bolus compared
with continuous administration,
2 (n = 28–78)
 Single drug compared with
placebo, 1 (n = 108)
 Opioid with/without adjuvant
analgesic compared with other
medical management,
2 (n = 143–154)
 Radiofrequency ablation, 0
 Cryoablation, 0
 Kiphoplasty, 1 RCT (n = 134);
1 case-series (n = 65)
 Vertebroplasty, 3 case-series
(n = 52, 106, 128)
 Celiac plexus block, 14 (n = 20–137)
 Superior Hypogastric plexus block,
1 (n = 50)
 Paravertebral blocks, 3 (n = 10)
 Blocks in the head region, 2 (n = 2)
 Plexus blocks, 6 (n = 13)
 Intercostal blocks, 2 (n = 43)
 Others, 4 (n = 11)
(1 study had had different types of
nerve blocks)
 Unilateral
cervical,
9 (n = 160)
Follow-up range  10–169 days  Kiphoplasty: RCT, 1 month
Case-series, 21 months
 Vertebroplasty:
6 weeks–17 months
 Celiac plexus block: 1 month–death
 Superior Hypogastric plexus block:
3 months
 5 days–death  2–28 days or
more
Pain relief  In all studies (comparisons of
groups’ mean scores)
 In all studies (majority by
comparisons of mean scores)
 One vertebroplasty series
reported analgesic efficacy of
86%–92%
 In the majority (comparisons of groups’
mean scores)
 In the majority  In the majority
Adverse effects  Few significant differences  Kiphoplasty:
RCT groups were similar
Case-series: 8%–12.1%
 Vertebroplasty:
2.3%–8.5%
 Celiac plexus block: decreased
opioid-induced adverse effects
 Hypogastric plexus block: no
difference
 Very few  Several, but
mostly transient
Evidence quality Low Low High—celiac plexus block
Low—hypogastric plexus block
Low Low
Recommendation in
favour or against the
interventions
Weak in favour Weak in favour of kyphoplasty
Weak against vertebroplasty
Strong in favour of celiac plexus block
Weak in favor of hypogastric plexus block
Weak in favour Weak in favour
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